Obermatt
See Similar Stocks →

Zymeworks

NSQ:ZYME · US98985Y1082
BiotechnologySmall

360

43
EV / EBIT75
Price / Owner Earnings82
Owner Earnings Yield1
Dividend Yield1
Price/Sales87
Price/Book37
Return on Capital48
Cash Return on Capital38
Return on Equity54
EBIT Margin6
Gross Profitability34
Accruals77
Owner Earnings Margin43
Sales growth86
Profit growth98
Reinvestment83
Price momentum67
Debt load39
Refinancing73
Debt Payback1
Liquidity32
Analyst ratings74
Opinion Changes50
Price Target Upside46
Market mood79
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Zymeworks doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2003
Employees270
Websitezymeworks.com
ISINUS98985Y1082
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyImmunologyPulmonologyRespiratoryInflammationHepatologyOncologyBiotechnologyMedicalTherapeutics

Description

Zymeworks Inc. (Zymeworks) is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditi…

Analysis

Middle-of-the-road

Zymeworks Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
66
2026

All-time high

66

Jun 2026

All-time low

51

Mar 2026

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
—
—
—
Price/Earnings
1
—
—
—
Price/Book
37
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
20
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zymeworks with its peers
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Elicio Therapeutics
NAQ:ELTX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Sutro Biopharma
NMQ:STRO
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →